Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: Results from a randomized, placebo‐controlled trial

Abstract

Patients with active AS showed significant sleep disturbance at baseline due to underlying pain associated with AS. Treatment with subcutaneous golimumab every 4 weeks significantly reduced sleep disturbance and improved health-related quality of life.